Vaccinex shares are trading lower. The company provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease.
Portfolio Pulse from Benzinga Newsdesk
Vaccinex shares are trading lower following an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of the pepinemab antibody in Alzheimer's disease.
October 31, 2024 | 4:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vaccinex shares are experiencing a decline after the company released new clinical findings from its SIGNAL-AD Phase 1b/2 trial of the pepinemab antibody for Alzheimer's disease.
The decline in Vaccinex's share price is directly linked to the market's reaction to the new clinical findings from the SIGNAL-AD trial. Investors may be concerned about the implications of these findings on the future success of the pepinemab antibody in treating Alzheimer's disease.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100